Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 97, showing 5 Applications out of 482 total, starting on record 21, ending on 25

# Protocol No Study Title Investigator(s) & Site(s)

21.

ECCT/24/04/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Fredrick Kipyego Sawe
Site(s) in Kenya
1. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
 
View

22.

ECCT/24/06/05   SII-qHPV Vaccine Study
    A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years.   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD Thika (Kiambu county)
2. KEMRI - CCR Nairobi (Nairobi City county)
 
View

23.

ECCT/24/04/05   Phase III Vitiligo Study
                                                                             A Double-Arm, Open Label, Phase III Study to Compare the                                           Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-                                                                                    UVB Light Alone in the Treatment of Vitiligo   
Principal Investigator(s)
1. Dr. Hannah Wanyika Wanyika
Site(s) in Kenya
Kenyatta National Hospital -
 
View

24.

ECCT/24/04/06   REACH 2
    Realizing Effectiveness Across Continents with Hydroxyurea (REACH):  A Phase I/II Prospective Trial of Hydroxyurea for Children and Young Adults with Sickle Cell Anaemia       
Principal Investigator(s)
1. Thomas Williams
2. Russell Ware
Site(s) in Kenya
Kilifi County Referal Hospital
 
View

25.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
View